NPPB and hydrops fetalis: One study observed adverse cardiovascular events >1 year after alloSCT in 25% of the patients, mostly driven by changes in markers for HF (NT-proBNP >500 ng/L and reduced left ventricular ejection fraction <45%), which were not included in our composite endpoint of cardiovascular events.